Lazanda
NDC Package 51772-311-04

11-digit billing NDC: 51772031104

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Lazanda is (fentanyl) nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Marketed by Archimedes Pharma Us Inc., this product is identified by NDC 51772-311 and is authorized under FDA application NDA022569.

Identification & Billing

NDC Package Code
51772-311-04
Package Description
4 BOTTLE, SPRAY in 1 CARTON / 8 SPRAY in 1 BOTTLE, SPRAY
Product Code
11-Digit Billing Format
51772031104
RxNorm Crosswalk
  • RxCUI: 1115573 - fentaNYL 100 MCG/ACTUAT Metered Dose Nasal Spray
  • RxCUI: 1115573 - fentanyl 0.1 MG/ACTUAT Metered Dose Nasal Spray
  • RxCUI: 1115573 - fentanyl (as fentanyl citrate) 100 MCG/ACTUAT Metered Dose Nasal Spray
  • RxCUI: 1115575 - Lazanda 100 MCG/ACTUAT Metered Dose Nasal Spray
  • RxCUI: 1115575 - fentanyl 0.1 MG/ACTUAT Metered Dose Nasal Spray [Lazanda]

Clinical Specifications

Proprietary Name
Lazanda
Dosage Form
-
Usage Information
Lazanda (fentanyl) nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least: 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer. Patients must remain on around-the-clock opioids when taking Lazanda.Lazanda is contraindicated for patients who are not already tolerant to opioids because life-threatening respiratory depression and death could occur in patients not taking chronic opioids. For this reason, Lazanda is contraindicated in the management of acute or postoperative pain, including headache/migraine, or dental pain. [4]Lazanda is intended to be prescribed only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

Regulatory & Marketing

Labeler Name
Archimedes Pharma Us Inc.
FDA Application #
NDA022569
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-17-2011
Listing Expiration
12-31-2018
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51772-311). Click a package code to view its specific billing and regulatory data.

1 BOTTLE, SPRAY in 1 CARTON / 8 SPRAY in 1 BOTTLE, SPRAY

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51772-311-04 identifies a specific commercial package of 4 bottle, spray in 1 carton / 8 spray in 1 bottle, spray of Lazanda, labeled by Archimedes Pharma Us Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Archimedes Pharma Us Inc. on October 17, 2011. The current certification is valid through December 31, 2018.

How is this Archimedes Pharma Us Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51772031104. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51772-311-04
11-Digit CMS (5-4-2)
51772-0311-04

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.